Navigation Links
Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Date:5/20/2008

al Meeting in March of this year. At that meeting, NCI investigators reported a 79% overall response rate in the 23 evaluable patients, including two complete responses. In addition to reporting an unprecedented rate of response in this patient group, the median hepatic progression free survival was reported to be 39 months.

The presentation was webcast live and will be available for ninety days and accessible at http://www.delcath.com .

About Delcath Systems, Inc.

Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested in Phase III and Phase II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver, including melanomas, neuroendocrine tumors and adenocarcinomas. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at http://www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
4. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
5. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
6. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
7. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
8. BioCryst Updates Peramivir Clinical Development Plan
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
11. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... Officer, will present at the CL King 12 th ... 9, 2014 at 12:30 p.m. ET. The conference will ... New York City . ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PR ... ("DelMar" "the Company") today announced the filing of June ... changed its fiscal year end to June 30th in ... stock on a national securities exchange in the timeliest ... with the United States Securities Exchange Commission can be ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
... (NYSE: BT ) shared its vision of ... cloud computing strategies to pharma research at the Bio-IT ... This vision reflects BT,s strong capabilities and increasing specialization ... world,s leading pharmaceutical companies rely on BT to support ...
Cached Medicine Technology:Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2BT Pushes for R&D Innovation at Bio-IT World Conference 2BT Pushes for R&D Innovation at Bio-IT World Conference 3
(Date:8/29/2014)... yesterday by the Mental Health Commission of Canada ... and education that police personnel receive. , "People ... Canada,s police community, and today,s report builds on ... people with mental illnesses," says Queen,s adjunct professor ... in the area of police psychology. "This is ...
(Date:8/29/2014)... New York, New York (PRWEB) August 29, 2014 ... died from cardiac arrest following a series of dialysis ... that alleges her death was the result of ... Liebhard LLP reports. The family’s lawsuit, which was file ... 2014, claims that the use of the products resulted ...
(Date:8/29/2014)... A team of scientists from the University of Colorado ... a process to expand production of stem cells used ... that extend beyond cancer, including treatments for inborn immunodeficiency ... article published Aug. 29 in PLOS ONE ... Regenerative Medicine and Stem Cell Biology and Taiga Biotechnologies, ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 ... poised to begin accepting applications next month for ... are transitioning into accepting marijuana as a legalized ... and dispensaries will be permitted to operate in ... communities will be best suited to handle legal ...
(Date:8/29/2014)... 2014 LiveOps, Inc., the global leader ... announced that LiveOps has been selected as a call ... of Strength Telethon for the third year in a ... awareness to support MDA’s mission to help children and ... fatal muscle disease. This year’s program includes performances by ...
Breaking Medicine News(10 mins):Health News:Report advocates improved police training 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 4Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Medical Marijuana Approaches Legalization in Chicago 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4
... , , SAN FRANCISCO, Sept. 22 ... will be a key driver of economic growth in the state over ... almost 1 million workers with a collective earning power of more than ... on whether California,s education system will be able to provide enough health ...
... Finding explains why obese children have higher relapse rates, ... Leukemia cells can hide in fat tissue to evade ... are more likely to develop chemotherapy resistance and have ... found that obese children with leukemia are 50 percent ...
... take into account side effects, researchers say , TUESDAY, ... advanced prostate cancer can increase the risk of heart ... be safer than others, new research has found. , ... advanced prostate cancer or prostate cancer that had spread ...
... Role of Innovation in Global Public Health , , ... Galien USA, the equivalent to the Nobel Prize for pharmaceutical research and ... research can improve health care across the U.S. and around the world. ... M.D., founder of Biogen and a member of the Prix Galien USA ...
... 22 The Neuropathy Association has announced two awardees ... , Every year, The Neuropathy Association--the leading ... neuropathies--awards two scientific research grants, each for $80,000 over ... This year,s grant recipients--Dennis Paul, Ph.D. and co-principal investigator, ...
... , Surgeons Urge Prompt Treatment for Growth Plate ... and outdoors, youth athletes stay active year-round in competitive sports, and for many ... American College of Foot and Ankle Surgeons advises that when a child complains ... warning sign of a serious foot problem. , , ...
Cached Medicine News:Health News:Report Finds Significant Job Opportunities for Californians in Allied Health; Questions State's Education Capacity To Train Workers 2Health News:Report Finds Significant Job Opportunities for Californians in Allied Health; Questions State's Education Capacity To Train Workers 3Health News:Leukemia Cells May Hide in Fat Tissue 2Health News:Hormone Therapy for Prostate Cancer Raises Heart Risks 2Health News:Prix Galien USA to Launch a Health Care Dialogue Among World-Leading Innovators in Science, Economics and Biotech 2Health News:Neuropathy Association Research Grants Advance the Understanding of Diabetic Neuropathy and Autoimmune Neuropathies 2Health News:Heel Pain in Youth Athletes: A Warning Sign 2
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
... anesthesia solution for the MRI environment , ... ,The Narkomed MRI-2 is the only ... monitor, designed and engineered to perform, without distance ... environments of up to 3.0 Tesla. This feature ...
... Narkomed GS provides high quality ventilation ... The proven technologies of the AV2+ ... the Narkomed GS user-friendly and intuitive. ... quality Narkomed GS is the perfect ...
... facilities where space is a premium Fabius ... delivery technologies with an ergonomic and compact ... of the Draeger Infinity patient monitoring range ... environment that is a sound investment into ...
Medicine Products: